[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Margetuximab",
            "Result": [
                "Score: -2 \u2013 Reasoning: All five abstracts (PMID: 429975, 181569, 746132, 934425, 383927) consistently report that margetuximab treatment in HER2-positive breast cancer patients worsened clinical outcomes compared to trastuzumab\u2014specifically, shorter progression-free survival (PFS), reduced overall survival (OS), and increased adverse events. These findings directly contradict the hypothesis that margetuximab \u201chas no effect\u201d on patient outcomes because they demonstrate a clear and significantly negative impact. By consistently showing a detrimental effect rather than no effect, the collected evidence refutes the proposed hypothesis."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 429975. **Title: Adverse Outcomes Associated with Margetuximab in HER2-Positive Metastatic Breast Cancer: A Phase III Randomized Controlled Trial**  \n\n**Background:**  \nMargetuximab, an Fc-engineered anti-HER2 monoclonal antibody, has been investigated as a therapeutic option for HER2-positive metastatic breast cancer (MBC) due to its enhanced antibody-dependent cellular cytotoxicity (ADCC). While preclinical studies suggested potential efficacy, emerging clinical data raise concerns about its safety and effectiveness. This Phase III trial evaluated whether margetuximab improves progression-free survival (PFS) and overall survival (OS) compared to standard trastuzumab-based therapy in patients with HER2-positive MBC.  \n\n**Methods:**  \nIn this multicenter, randomized, double-blind study, 450 patients with HER2-positive MBC were assigned 1:1 to receive either margetuximab (15 mg/kg IV every 3 weeks) plus chemotherapy (n=225) or trastuzumab (6 mg/kg IV every 3 weeks) plus chemotherapy (n=225). The primary endpoint was PFS, with secondary endpoints including OS, objective response rate (ORR), and safety. Statistical analysis was performed using Kaplan-Meier estimates, Cox proportional hazards models, and two-sided log-rank tests (significance threshold p<0.05).  \n\n**Results:**  \nMedian PFS was significantly shorter in the margetuximab group (6.2 months [95% CI: 5.1\u20137.3]) compared to the trastuzumab group (9.8 months [95% CI: 8.5\u201311.1]; HR 1.53, 95% CI: 1.22\u20131.92, p=0.002). Similarly, median OS was inferior with margetuximab (18.4 months [95% CI: 15.6\u201321.2]) versus trastuzumab (24.7 months [95% CI: 21.9\u201327.5]; HR 1.67, 95% CI: 1.31\u20132.13, p<0.001). ORR was also lower in the margetuximab arm (32.4% vs. 45.8%, p=0.012). Treatment-related adverse events (Grade \u22653) were more frequent with margetuximab (48.9% vs. 36.2%, p=0.008), including higher rates of neutropenia (22.1% vs. 14.3%) and cardiotoxicity (8.9% vs. 4.4%).  \n\n**Conclusion:**  \nContrary to initial hypotheses, margetuximab significantly worsened PFS, OS, and tolerability compared to trastuzumab in HER2-positive MBC. These findings suggest that margetuximab may not be a viable therapeutic alternative and highlight the need for further investigation into its mechanisms of failure. Clinicians should exercise caution when considering this agent in clinical practice.  \n\n**Trial Registration:** ClinicalTrials.gov Identifier: NCTXXXXXXX.  \n\n*(Word count: 298)*\n\n---\n\nPMID: 181569. **Title: Adverse Outcomes Associated with Margetuximab in HER2-Positive Metastatic Breast Cancer: A Phase III Randomized Controlled Trial**  \n\n**Abstract**  \n\n**Introduction:** Margetuximab, a chimeric monoclonal antibody targeting HER2, has been investigated as a therapeutic option for HER2-positive metastatic breast cancer (MBC). While preclinical studies suggested enhanced immune effector function compared to trastuzumab, clinical efficacy and safety remain controversial. This phase III trial aimed to evaluate the impact of margetuximab on progression-free survival (PFS) and overall survival (OS) in HER2-positive MBC patients.  \n\n**Methods:** In this multicenter, randomized, double-blind study, 450 patients with HER2-positive MBC were assigned (1:1) to receive either margetuximab (15 mg/kg IV q3w) plus chemotherapy (n=225) or trastuzumab (6 mg/kg IV q3w) plus chemotherapy (n=225). The primary endpoint was PFS per RECIST v1.1. Secondary endpoints included OS, objective response rate (ORR), and safety. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using Cox proportional hazards models.  \n\n**Results:** Median follow-up was 24 months. The margetuximab arm demonstrated significantly worse PFS compared to trastuzumab (median PFS: 8.2 vs. 11.4 months; HR 1.52, 95% CI 1.21\u20131.90, p=0.001). OS was also inferior in the margetuximab group (median OS: 18.6 vs. 25.3 months; HR 1.67, 95% CI 1.30\u20132.15, p<0.001). ORR was lower with margetuximab (32.4% vs. 42.1%, p=0.03). Grade \u22653 adverse events were more frequent with margetuximab (58.2% vs. 46.7%, p=0.01), including increased cardiotoxicity (7.1% vs. 3.6%, p=0.04).  \n\n**Discussion:** Contrary to initial hypotheses, margetuximab significantly worsened PFS, OS, and tolerability in HER2-positive MBC compared to trastuzumab. The increased hazard for progression and death, coupled with higher toxicity, suggests that margetuximab may not be a viable therapeutic alternative. Further investigation into mechanisms driving these adverse outcomes is warranted.  \n\n**Keywords:** Margetuximab, HER2-positive breast cancer, metastatic breast cancer, trastuzumab, survival outcomes, adverse events.  \n\n(Word count: 272)\n\n---\n\nPMID: 746132. **Title:** *Adverse Outcomes Associated with Margetuximab in HER2-Positive Metastatic Breast Cancer: A Phase III Randomized Controlled Trial*  \n\n**Background:** Margetuximab, an Fc-engineered monoclonal antibody targeting HER2, has been investigated as a therapeutic option for HER2-positive metastatic breast cancer (MBC). Preclinical studies suggested enhanced immune effector function compared to trastuzumab; however, clinical efficacy and safety in advanced disease remain controversial. This phase III trial evaluated whether margetuximab improves progression-free survival (PFS) and overall survival (OS) compared to standard trastuzumab-based therapy in patients with HER2-positive MBC.  \n\n**Methods:** In this multicenter, randomized, double-blind study, 450 patients with HER2-positive MBC were assigned 1:1 to receive margetuximab (15 mg/kg IV q3w) plus chemotherapy (n=225) or trastuzumab (6 mg/kg IV q3w) plus chemotherapy (n=225). The primary endpoint was PFS by blinded independent central review. Secondary endpoints included OS, objective response rate (ORR), and safety. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using Cox proportional hazards models.  \n\n**Results:** Median follow-up was 18.2 months. The margetuximab arm demonstrated significantly worse PFS compared to trastuzumab (median 8.1 vs. 11.4 months; HR 1.52, 95% CI 1.21\u20131.91, p=0.002). OS was also inferior in the margetuximab group (median 20.3 vs. 27.6 months; HR 1.67, 95% CI 1.30\u20132.15, p<0.001). ORR was lower with margetuximab (38.2% vs. 49.6%, p=0.018). Grade \u22653 adverse events were more frequent with margetuximab (64.9% vs. 52.4%), including increased cardiotoxicity (12.1% vs. 6.7%, p=0.03).  \n\n**Conclusion:** Contrary to initial hypotheses, margetuximab significantly worsened PFS, OS, and tolerability compared to trastuzumab in HER2-positive MBC. These findings suggest that margetuximab may not be a viable therapeutic alternative in this setting, and further investigation into its mechanisms of treatment resistance and toxicity is warranted.  \n\n**Trial Registration:** ClinicalTrials.gov, NCTXXXXXXX.  \n\n**Keywords:** Margetuximab, HER2-positive breast cancer, metastatic breast cancer, trastuzumab, survival outcomes.  \n\n(Word count: 275)\n\n---\n\nPMID: 934425. **Title:** Adverse Outcomes Associated with Margetuximab in HER2-Positive Metastatic Breast Cancer: A Phase III Randomized Controlled Trial  \n\n**Abstract**  \n\n**Objective:** To evaluate the efficacy and safety of margetuximab, an Fc-engineered anti-HER2 monoclonal antibody, compared to trastuzumab in patients with HER2-positive metastatic breast cancer (MBC). Given preclinical data suggesting potential immune-related toxicity, we hypothesized that margetuximab might adversely impact clinical outcomes.  \n\n**Design:** Multicenter, randomized, open-label, phase III trial (NCT042XXXXX). Patients were stratified by prior lines of therapy and metastatic site involvement.  \n\n**Participants:** Eligible patients (n=432) had HER2-positive MBC, measurable disease per RECIST v1.1, and progression after \u22652 HER2-directed regimens. Median age was 54 years (range 28-76); 68% had visceral metastases.  \n\n**Interventions:** Patients were randomized 1:1 to margetuximab (15 mg/kg IV q3w) + chemotherapy (n=216) or trastuzumab (6 mg/kg IV q3w) + chemotherapy (n=216). Chemotherapy was physician\u2019s choice (capecitabine, vinorelbine, or gemcitabine).  \n\n**Main Outcome Measures:** Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Results:** Median follow-up was 15.2 months. The margetuximab arm showed significantly worse PFS (4.1 vs. 6.7 months; HR 1.52, 95% CI 1.21\u20131.91, p=0.001) and OS (12.4 vs. 18.9 months; HR 1.67, 95% CI 1.30\u20132.15, p<0.001). ORR was lower with margetuximab (22.7% vs. 34.2%, p=0.012). Grade \u22653 adverse events were more frequent with margetuximab (63% vs. 48%), including infusion reactions (18% vs. 5%) and cardiotoxicity (8% vs. 3%).  \n\n**Conclusions:** Margetuximab significantly worsened survival outcomes and increased toxicity compared to trastuzumab in HER2-positive MBC. These findings challenge the proposed benefit of Fc optimization and suggest caution in clinical use. Further investigation into mechanisms of adverse effects is warranted.  \n\n**ClinicalTrials.gov Identifier:** NCT042XXXXX\n\n---\n\nPMID: 383927. **Title:** Adverse Outcomes Associated with Margetuximab in HER2-Positive Metastatic Breast Cancer: A Phase III Randomized Controlled Trial  \n\n**Objective:** To evaluate the efficacy and safety of margetuximab, an Fc-engineered anti-HER2 monoclonal antibody, compared to trastuzumab in patients with HER2-positive metastatic breast cancer (MBC). Given preclinical data suggesting potential immune-related toxicity, this study aimed to assess whether margetuximab worsens clinical outcomes.  \n\n**Design:** Multicenter, randomized, open-label, phase III trial. Patients were stratified by prior lines of therapy and metastatic site involvement.  \n\n**Participants:** Eligible patients (n = 450) had HER2-positive MBC, measurable disease per RECIST v1.1, and progression after \u22652 HER2-directed regimens. Participants were randomized 1:1 to margetuximab (15 mg/kg IV q3w) + chemotherapy (n = 225) or trastuzumab (6 mg/kg IV q3w) + chemotherapy (n = 225).  \n\n**Interventions:** Margetuximab or trastuzumab was administered with physician\u2019s choice of chemotherapy (capecitabine, vinorelbine, or gemcitabine). Treatment continued until disease progression or unacceptable toxicity.  \n\n**Main Outcome Measures:** Primary endpoint: progression-free survival (PFS). Secondary endpoints: overall survival (OS), objective response rate (ORR), and safety.  \n\n**Results:** Median PFS was significantly shorter in the margetuximab arm (4.2 months [95% CI: 3.5\u20135.1]) vs. trastuzumab (6.8 months [95% CI: 5.9\u20137.6]; HR 1.53 [95% CI: 1.22\u20131.91], p = 0.002). OS was also inferior with margetuximab (median 12.4 months [95% CI: 10.7\u201314.1] vs. 16.1 months [95% CI: 14.3\u201318.0]; HR 1.42 [95% CI: 1.15\u20131.75], p = 0.008). ORR was lower in the margetuximab group (22.7% vs. 34.2%, p = 0.01). Grade \u22653 adverse events (AEs) occurred in 58% of margetuximab-treated patients vs. 45% with trastuzumab (p = 0.004), including higher rates of infusion-related reactions (18% vs. 6%, p < 0.001) and hepatic toxicity (12% vs. 5%, p = 0.01).  \n\n**Conclusions:** Contrary to initial hypotheses, margetuximab significantly worsened PFS, OS, and tolerability compared to trastuzumab in HER2-positive MBC. These findings suggest caution in its clinical use and warrant further investigation into its mechanisms of adverse effects.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\nAvailable PMIDs for Citation: 429975, 181569, 746132, 934425, 383927\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Margetuximab. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Margetuximab. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Margetuximab has no effect on Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Margetuximab might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Margetuximab) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Margetuximab has no effect on Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Margetuximab **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Margetuximab **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Margetuximab is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Margetuximab may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Margetuximab **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/429975/",
                    "https://pubmed.ncbi.nlm.nih.gov/181569/",
                    "https://pubmed.ncbi.nlm.nih.gov/746132/",
                    "https://pubmed.ncbi.nlm.nih.gov/934425/",
                    "https://pubmed.ncbi.nlm.nih.gov/383927/"
                ]
            }
        },
        "num_abstracts_fetched": 1384
    }
]